Arkolith/Insider Trading/ABUS/Form 4

McElhaugh Michael J.

Interim President & CEO, DirectorArbutus Biopharma Corp (ABUS) · full profile →Form 4 · filed Feb 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$23K
Net Open-Market Flow
-$23K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2024Sell(S)10K$2.31$23K1.5M
Feb 1, 2024Grant(A)124K—$01.5M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)495K—$0495K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001447028-24-000025) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML